Genome-Wide Screening for Genetic Alterations in Esophageal Cancer by aCGH Identifies 11q13 Amplification Oncogenes Associated with Nodal Metastasis by Ying, Jianming et al.
Genome-Wide Screening for Genetic Alterations in
Esophageal Cancer by aCGH Identifies 11q13
Amplification Oncogenes Associated with Nodal
Metastasis
Jianming Ying
1,2*, Ling Shan
1, Jisheng Li
2,3, Lan Zhong
2, Liyan Xue
1, Hong Zhao
4, Lili Li
2,
Cordelia Langford
5, Lei Guo
1, Tian Qiu
1, Ning Lu
1*, Qian Tao
2*
1Department of Pathology, Cancer Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, 2Cancer Epigenetics Laboratory,
Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese
University of Hong Kong, Hong Kong, 3Department of Chemotherapy, Cancer Center, Qilu Hospital, Shandong University, Jinan, China, 4Department of Abdominal
Surgical Oncology, Cancer Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, 5Microarray Facility, Wellcome Trust Sanger
Institute, Cambridge, United Kingdom
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is highly prevalent in China and other Asian countries, as a major
cause of cancer-related mortality. ESCC displays complex chromosomal abnormalities, including multiple structural and
numerical aberrations. Chromosomal abnormalities, such as recurrent amplifications and homozygous deletions, directly
contribute to tumorigenesis through altering the expression of key oncogenes and tumor suppressor genes.
Methodology/Principle Findings: To understand the role of genetic alterations in ESCC pathogenesis and identify critical
amplification/deletion targets, we performed genome-wide 1-Mb array comparative genomic hybridization (aCGH) analysis
for 10 commonly used ESCC cell lines. Recurrent chromosomal gains were frequently detected on 3q26-27, 5p15-14, 8p12,
8p22-24, 11q13, 13q21-31, 18p11 and 20q11-13, with frequent losses also found on 8p23-22, 11q22, 14q32 and 18q11-23.
Gain of 11q13.3-13.4 was the most frequent alteration in ESCC. Within this region, CCND1 oncogene was identified with high
level of amplification and overexpression in ESCC, while FGF19 and SHANK2 was also remarkably over-expressed. Moreover,
a high concordance (91.5%) of gene amplification and protein overexpression of CCND1 was observed in primary ESCC
tumors. CCND1 amplification/overexpression was also significantly correlated with the lymph node metastasis of ESCC.
Conclusion: These findings suggest that genomic gain of 11q13 is the major mechanism contributing to the amplification.
Novel oncogenes identified within the 11q13 amplicon including FGF19 and SHANK2 may play important roles in ESCC
tumorigenesis.
Citation: Ying J, Shan L, Li J, Zhong L, Xue L, et al. (2012) Genome-Wide Screening for Genetic Alterations in Esophageal Cancer by aCGH Identifies 11q13
Amplification Oncogenes Associated with Nodal Metastasis. PLoS ONE 7(6): e39797. doi:10.1371/journal.pone.0039797
Editor: Masaru Katoh, National Cancer Center, Japan
Received October 6, 2011; Accepted May 30, 2012; Published June 25, 2012
Copyright:  2012 Ying et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the National Natural Science Foundation of China (#30801344, #30928012) and the Beijing Nova Program
(No. 2009A70). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: qtao@cuhk.edu.hk (QT); nlu03@126.com (NL); jmying@hotmail.com (JY)
Introduction
Esophageal cancer is one of the most aggressive malignancies
originated in the gastrointestinal tract, and ranks as the sixth
leading cause of cancer-related deaths in the world [1]. Its
incidence varies greatly among different regions worldwide, with
China as a high-risk area. In some districts of north and central
China, its incidence exceeds 100 cases/per 100,000 per year [2].
Histologically, esophageal cancer is classified as esophageal
adenocarcinoma and esophageal squamous cell carcinoma
(ESCC). Most of the cases reported in US are esophageal
adenocarcinomas, however in China and other Asian countries,
ESCC is the predominant type that accounts for about 90% of all
cases. Despite advances in multimodal therapies, ESCC remains
a serious cancer-care problem in many countries with very low 5-
year survival rates (,30%) [3]. Thus, it is of great clinical value to
look for sensitive and specific biomarkers for the early detection
and prognosis of this malignancy, as well as novel therapeutic
targets.
Genomic amplifications and deletions contribute to human
tumorigenesis by altering the expression levels of critical
oncogenes and tumor suppressor genes (TSGs). In spite of its
high prevalence, ESCC has not been studied as intensively as its
adenocarcinoma counterpart. Efforts have been put to identify
gross copy number alterations of both ESCC cell lines and
tumors, including karyotyping, fluorescence in situ hybridization
(FISH), conventional comparative genome hybridization (CGH)
and loss of heterozygosity (LOH) analyses. According to available
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amplifications in ESCC are 3q, 4q, 5p, 8p, 7q, 9q, 10q21,
11q13-q22, 18p11.3, 20q and 22qtel [4–12]. Amplifications
harboring oncogenes, e.g. 11q13 (CCND1, EMS1), 3q26
(EIF5A2), 21q22 (ETS2), 8q24 (MYC), have been consistently
observed in more than one studies [4–12]. Chromosomal losses
recurrently involve 3p, 5q, 9p, 13q, 18q and 21q, in which target
genes such as FHIT, APC, RB1 and CDKN2A are located [4–12].
In recent years, high resolution array-based CGH (aCGH) has
been applied to identify target oncogenes and TSGs through
defining recurrent gains and losses in various cancers. Until
recently, two studies performed aCGH analysis on primary
ESCC samples, revealing recurrent, high-level amplifications in
3q27.1, 7p11, 8q21.11, 8q24.21, 11q13.3, 11q22, 12q15–q21.1,
18q11.2, and 19q13.11–q13.12, and homozygous deletions in
4q34.3–q35.1 and 9p21.3 [13;14]. However, compared to
‘‘pure’’ ESCC cell lines, primary ESCC samples contain lots of
normal cells which may affect aCGH results in different ways.
Although several comprehensive whole genome studies on ESCC
cell lines has been reported, the cell lines used are mainly
originated from Japanese ESCC (TE series) and South African
ESCC patients, respectively [15–17]. Profiling of multiple ESCC
cell lines originated from different high-risk areas in Asian via
aCGH will not only allow the identification of recurrent
chromosomal changes in Asian ESCC, but also provide valuable
insight for future studies using these cells lines as ESCC models.
In this study, we profiled 10 commonly used ESCC cell lines
originated from mainland Chinese (EC1, EC18 and EC109),
Hong Kong Chinese (HKESC1, HKESC2, HKESC3 and
SLMT1) and Japanese (KYSE70, KYSE410 and KYSE520)
patients for whole-genome DNA copy number alterations using
aCGH analysis. Among identified alterations, amplification of
11q13 is the most frequent gain observed, harboring FGF19,
SHANK2 and CCND1. We further found that CCND1 expression
was frequently upregulated in primary ESCC tumors, and DNA
amplification contributes to its overexpression, which is correlated
with lymph node metastasis of primary ESCC tumors.
Results
Genomic Profiles of ESCC Cell Lines by 1-Mb aCGH
Ten ESCC cell lines were analyzed using 1-Mb aCGH (Sanger
3040-BAC/PAC clone array). Signal intensity ratios for each BAC
were processed and displayed as log2 plots using SeeGH software
[18]. Figure 1 shows the representative SeeGH karyograms of one
ESCC cell line (EC18) analyzed, demonstrating the identification
of various gains and losses. Other SeeGH karyograms of ESCC
cell lines analyzed are shown in Figure S1. Figure 2 summarizes
the recurrently altered regions (with log2 ratios more than 1 or less
than 21). In general, chromosomal gains were more frequently
detected than losses. The most frequent alterations include gain of
11q13 (70%) and complete loss of 18q11-23 (50%). Other gains
occurring in three or more cell lines are 3q26-27 (40%), 5p15-14
(50%), 8p12 (30%), 8p22-24 (30%), 13q21-31 (30%), 18p11 (30%)
and 20q11-13 (40%). Other losses occurring in three or more cell
lines are 8p23-22 (40%), 11q22 (30%) and 14q32 (30%) (Fig. 2).
Amplification and Overexpression of 11q13 Genes in
ESCC Cell Lines
Among regions identified with recurrent alterations, amplifica-
tion of 11q13.3-13.4 is the most frequent gain in ESCC (Fig. 3A),
especially in those cell lines derived from Chinese patients (6/7 cell
lines, 85%). Several genes with potential oncogenic functions have
been identified in this locus, including CCND1 and CTTN. Thus,
11q13 was further investigated for the confirmation of gains and
identification of amplified genes, by duplex genomic DNA PCR in
10 ESCC cell lines. CCND1 is mapped to the center of the 11q13
amplicon, and high-level amplification of CCND1 was confirmed
in 6/10 cell lines (Fig. 3B, C), while CTTN exhibited the second
highest level of amplification (in 5/10 cell lines).
Several genes around CCND1 at 11q13 were further examined
by semi-quantitative RT-PCR in ESCC cell lines. Results showed
that FGF19 and SHANK2 were also remarkably overexpressed in
ESCC cell lines, while only weakly or not expressed in normal
esophagus or immortalized normal cells (Fig. 4), although no
obvious amplification of SHANK2 was detected in these cell lines.
FGF3 (data not shown) and 4 were basically not expressed in any
ESCC cell line or normal esophagus. Overexpression of CCND1
and CTTN was also observed in most ESCC cell lines when
compared to normal esophagus, although they were generally
expressed in normal esophagus and immortalized cells (Fig. 4).
Taken together, these data confirmed that 11q13 is the most
frequent amplification in ESCC and delineated several genes
including CCND1, CTTN, FGF19 and SHANK2, as potential
critical oncogenes affected.
CCND1 Overexpression in Primary ESCC and its
Clinicopathological Association
Expression of CCND1 protein was further investigated by
immunohistochemistry in ESCC tissue microarray (TMA) of 171
primary ESCC and adjacent surgical margin histologic normal
esophageal tissues. Cases with .10% of tumor cells showing
positive nuclear staining were scored for CCND1 overexpression.
Ninety-four of the 171 cases (55%) showed CCND1 over-
expression, including 42 cases of grade 1+, 35 cases of grade 2+
and 17 cases of grade 3+ (Fig. 5A). In contrast, only scattered
positive cells were found in basal cells of the normal esophageal
epithelia.
We then tested the correlation between CCND1 overexpression
and clinicopathological features, including tumor size, grade,
lymph node metastasis, and patient age. CCND1 overexpression
was significantly associated with lymph node metastasis (p=0.006)
(Table 1), but not with pT, grade, or patient age (p.0.05,
respectively). In the cases with CCND1 overexpression, there was
no significant difference regarding lymph node metastasis,
between CCND1 high-expression groups (grade 2+ and 3+) and
the low-expression group (grade 1+)( p=0.37).
CCND1 Overexpression Resulting from Gene
Amplification but Not Activated b-catenin Signaling
To confirm the gene amplification of CCND1 in primary ESCC
and investigate the association with its overexpression, we applied
fluorescence in situ hybridization (FISH) analysis with commercial
CCND1 probe together with CEP 11 probe in 94 cases. CCND1
was amplified in 50 cases (53.2%) and not-amplified in 44 cases
(46.8%) (Fig. 5B). Furthermore, gene amplification by FISH and
protein overexpression by immunohistochemistry for CCND1
showed 91.5% (k=0.69) concordance.
Immunohistochemically, nuclear staining for b-catenin was
positive in only 4/94 cases (4.3%). All b-catenin positive cases
were negative for CCND1 by immunohistochemistry.
Discussion
ESCC is the sixth most fatal cancer worldwide and accounts for
90% cases of all esophageal cancers in China [19]. Although the
incidence of ESCC is low in Western countries, this tumor is
common in Asia, especially in some regions in China like Henan
CCND1 Amplification in Esophageal Cancer
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mental and genetic factors contribute to ESCC pathogenesis.
Tobacco, alcohol, hot drink/food, dietary deficiency and achalasia
have been considered as major environmental risk factors for
ESCC, as revealed by epidemiology studies [21;22]. Meanwhile,
cytogenetic and molecular genetic analyses demonstrated multiple
genetic abnormalities in ESCC, including chromosomal losses and
gains. Elucidation of these aberrations will lead to better un-
derstanding of ESCC pathogenesis, and further develop thera-
peutics and biomarkers for the prediction of metastasis and
prognosis. In this study, we carried out a comprehensive in-
vestigation of genomic abnormalities in ESCC by high-resolution
array-based CGH, to delineate the minimal chromosomal regions
of amplifications and deletions. The results provide detailed
pictures of multiple genetic lesions in ESCC genomes, and also
give hints for further identification of critical oncogenes and TSGs
in this malignancy.
Consistent with previous findings [4–14], recurrent gains
including 11q13 (CCND1, EMS1), 3q26 (EIF5A2), 21q22 (ETS2 )
and 8q24 (MYC), and losses including 3p, 5q, 9p, 13q, 18q and
21q with target genes such as FHIT, APC, RB1 and CDKN2A, were
identified in ESCC cell lines in this study. Among amplicons
detected, 11q13.3-13.4 is the most frequently amplified chromo-
somal region. Two genes, CCND1 and CTTN located in this
region, were identified with high-level amplifications in multiple
ESCC cell lines. While investigated at the mRNA level, we found
several genes, including CCND1 CTTN, FGF19 and SHANK2, were
frequently overexpressed in ESCC cell lines. Recently, Sawey et al
reported that CCND1 and FGF19 were two driving oncogenes in
hepatocellular carcinoma [23]. In this study, we focused on
CCND1. Our study confirmed frequent amplification (53.2%) and
concordant protein over-expression (51.1%) of CCND1 in primary
ESCC. Moreover, a positive correlation between CCND1 ampli-
fication/overexpression and lymph node metastasis in ESCC was
observed, indicating that CCND1 may serve as a prognostic marker
for ESCC, in line with other studies ([24–27]. In addition to
amplification, CCND1 overexpression may be driven by tran-
scriptional regulation, such as the Wnt signaling pathway. Beta-
catenin is a key member of the Wnt signaling pathway, which has
been suggested involved in esophageal cancer initiation and
progression [28]. In this study, only 4.3% (4 in 94) of ESCC cases
were identified with beta-catenin nuclear expression. The results
indicate that the genomic gain of 11q13 in ESCC is the primary
mechanism resulting in CCND1 amplification and overexpression.
This mechanism has also been reported in other tumor types such
as head and neck carcinoma [29], pituitary tumors [30], and
breast cancer [31].
CTTN is an actin-associated scaffolding protein, binds and
activates actin-related protein complex (Arp2/3) and thus
regulates the branched actin networks in the formation of dynamic
cortical actin associated structures. CCND1 and CTTN are
frequently co-amplified in cancers [32–34]. Previously, CTTN
has been identified as a bona fide oncogene located at 11q13
involved in ESCC carcinogenesis, contribute to the metastasis of
various caners including ESCC, breast, hepatocellular, and head
and neck squamous cell carcinomas [32–34]. FGF19, a fibroblast
growth factor, together with CCND1, was recently reported to
a major driver oncogene in hepatocellular carcinoma [23]. The
Figure 1. Whole genome profile of an ESCC cell line (EC18) by 1-Mb aCGH. Normalized log2 signal intensity ratios were plotted using SeeGH
software. A log2 signal ratio of 0 represents equivalent copy number between the sample and the reference DNA (details in Materials and Methods).
Cytoband pattern for each chromosome is shown in the left. Vertical lines denote log2 signal ratios from 22t o+2 with copy number increasing in
the right and decreasing in the left. Each dark blue dot represents a single BAC clone.
doi:10.1371/journal.pone.0039797.g001
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ESCC pathogenesis and the related molecule mechanisms needs
to be further investigated.
Among other frequent chromosomal gains, 3q26-27 is a novel
amplicon detected in ESCC. Well-known oncogenes residing in
this region include EVI1, EIF5A2 and PIK3CA, which have been
reported to exhibit potential oncogenic functions. In addition,
TRIO and CTNND2 at 5p, MYC at 8q22, KLF5 and POU4F1 at
13q and NKX2.2 at 20p were also considered to play oncogenic
roles in other tumors [35;36] and might contribute to ESCC
carcinogenesis. Regions of high-level deletions containing known
or candidate TSGs were also detected, including 18q11-23
containing SMAD2, SMAD4 and DCC (EC1, EC109, HKESC3,
SLMT1 and KYSE70), 8p22 containing DLC1 (EC1, KYSE70,
410 and 520) and a region on 14q32 containing DLK1 and MEG3
(EC1, EC109 and KYSE70). Other high-level deletions containing
candidate TSGs include 4q21.23-21.3 (MAPK10, PTPN13 and
ARGAP24), 7p21.2 (DGKB), 7q35 (CNTNAP2), 8q11 (CEBPD),
10p11 (PARD3), 13q31.1 (SPRY2) and 16q22-23 (ATBF1). Most of
these deleted regions of ESCC have also been reported in one or
more other cancer types [37;38]. Importantly, genetic/epigenetic
disruptions or altered expression levels of some TSG candidates
mentioned above, including SMAD2, SMAD4, DCC, DLC1 and
PARD3, have been reported in ESCC tumors and cell lines,
indicating that aCGH study using multiple tumor cell lines could
facilitate the identification of critical cancer genes in human
tumors. [39–42].
In conclusion, multiple minimal regions of deletions and
amplicons were detected in 10 commonly used ESCC cell lines
in this study, and several novel oncogenes located in the most
frequently amplified region 11q13, including FGF19, SHANK2 and
CCND1, have been identified. This study provides crucial data for
further identification and characterization of critical oncogenes
and TSGs involved in ESCC pathogenesis.
Materials and Methods
Cell Lines
Ten ESCC cell lines (EC1, EC18, EC109, HKESC1,
HKESC2, HKESC3 and SLMT1 are from Chinese patients,
while KYSE70, KYSE410 and KYSE520 are from Japanese
patients) and three immortalized normal esophageal epithelial cell
lines (Het-1A, NE1 and NE3) were used in the study [43]. Cell
lines were maintained in RPMI-1640 (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT),
cultured in 5% CO2 at 37uC.
Figure 2. Minimal aberrant regions identified by aCGH. Abnormalities with $20% frequency in 10 ESCC cell lines are shown. * Regions with
abnormalities in $50% cell lines are shown in bold.
doi:10.1371/journal.pone.0039797.g002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39797Figure 3. CCND1 is located at the center of the 11q13 amplicon in ESCC. A, aCGH profiles of six ESCC cell lines at the CCND1 locus.
Normalized log2 signal ratios were plotted. Amplifications were defined as log2 signal intensities $1. Horizontal lines denote log2 signal ratios from
21 to 3 with copy number increasing upwards. Each black/colorful dot represents a single BAC clone. Names of related BAC clones are also shown.
Transcript map of the core 11q13 amplicon is shown in the bottom. B, Semi-quantitative duplex genomic DNA PCR analysis of CCND1 in 10 ESCC cell
lines and 3 normal PBMC samples. Signal intensity ratios of CCND1/GAPDH are shown. C, Summary of gene copy number changes of several genes
within the 11q13 amplicon. Numbers shown in the table are folds of copy numbers of ESCC cell lines relative to the mean values of three PBMC
samples. PBMC, peripheral blood mononuclear cell.
doi:10.1371/journal.pone.0039797.g003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39797Figure 4. Expression levels of several 11q13 genes around CCND1 in ESCC cell lines examined by semi-quantitative RT-PCR. The
amplification status of 11q13 region by aCGH and CCND1 by multiplex DNA PCR are listed at the bottom. +, amplified; -, not amplified. 23x, 25x, 30x:
RT-PCR cycles. All other genes were examined by RT-PCR with 30 cycles, with GAPDH for only 23 cycles.
doi:10.1371/journal.pone.0039797.g004
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A total of 171 formalin-fixed paraffin-embedded (FFPE)
Chinese ESCC samples (from 2007 to 2008) and adjacent surgical
margin histological normal esophageal tissues were obtained, after
receiving patients’ written informed consents and Institutional
Review Board (IRB) approval from the Cancer Hospital, Chinese
Academy of Medical Sciences, Beijing, China. All patients were
previously untreated (i.e., with no chemotherapy or radiotherapy),
with resectable primary tumors. The mean age of patients was 58
years (range 33–78), and male to female ratio was 4.2: 1 (138: 33).
Hematoxylin and eosin (HE)-stained sections were reviewed to
confirm the diagnosis and define tumor areas. Tumor stage (pT)
and grade were defined according to the current WHO
classification of tumors.
Figure 5. Representative immunohistochemical staining and FISH analysis. A, Top panels, immunohistochemical staining for CCND1. Left,
scattered positivity of CCND1, especially in the basal layer, is seen in normal esophageal epithelium (original magnification, 6200). Middle, a case of
ESCC is negative for CCND1 expression (original magnification, 6200). Right, diffuse and strong nuclear staining for CCND1 in this case of ESCC
(original magnification, 6200). Bottom panels, FISH analysis. Green signals refer to reference probe of chr 11 centromere while red signals are target
probe for CCND1. Left, unamplified in normal esophageal epithelium, Middle, an unamplified ESCC case. Right, an amplified ESCC case. B. Results of
CCND1 amplification and expression levels in 94 paraffin-embedded primary ESCC.
doi:10.1371/journal.pone.0039797.g005
Table 1. Overexpression of CCND1 was associated with
lymph node metastasis.
CCND1 expression p value
Positive Negative
Differentiation Well 18 11 0.62*
Moderate 48 39
Poor 28 27
Lymph Node
Metastasis
No 35 45 0.006*
Yes 59 32
doi:10.1371/journal.pone.0039797.t001
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High-molecular-weight chromosomal DNA was isolated from
cell lines using Qiagen kit (Qiagen, Hilgen, Germany). The purity
and molecular weight of DNA were examined on agarose gels. 1-
Mb resolution whole-genome arrays with 3040 BAC/PAC clones
were provided by Sanger Institute, UK (http://www.sanger.ac.
uk/Projects/Microarrays/) [44]. Clones details are listed in
Ensembl (http://www.ensembl.org/Homo_sapiens/index.html).
Array-CGH was performed with slight modifications [43–45].
Briefly, sample DNA (600 ng) was labeled with Cy5-dCTP
(Amersham Pharmacia), whereas reference DNA of normal
peripheral blood mononuclear cells (PBMCs) from healthy
Chinese donors with Cy3-dCTP using the BioPrime Array CGH
Genomic Labeling System (Invitrogen, Carlsbad, CA). Unincor-
porated nucleotides were removed using Purification Module
supplied in the labeling system. Labeled samples and normal DNA
(50 ml each) were mixed and ethanol precipitated together with
67.5 ml of human Cot-1 DNA (Invitrogen). Then, the mixed DNA
were resuspended in 30 ml of hybridization buffer, denatured and
prehybridized in a humidity chamber inside a hybridization oven
at 5 rpm for 2 hrs at 37uC. The prehybridization mixture was
prepared as follows: 80 ml of Herring Sperm DNA (10 mg/ml,
Sigma) and 67.5 ml of human Cot-1 DNA (Invitrogen) were
precipitated, resuspended in 120 ml of hybridization buffer and
denatured for 10 min at 72uC. After prehybridization, the
prehybridized probe was added onto the slide, and incubated at
5 rpm for 48 hours at 37uC. Slides were rinsed and washed three
times, air-dried and stored at 4uC.
Hybridized slides were scanned using an Axon 4000B scanner
(Axon Instruments Inc, Union City, CA) and analyzed with the
GenePixPro 4.0 image analysis software where the spots were
defined and median fluorescence intensities were calculated. The
background subtracted fluorescence intensities were imported into
a custom-designed Microsoft Excel spreadsheet template. A
particular spot was excluded if the duplicate spots have a difference
of .10%. The mean values of duplicate spots were presented in
graphical output in the form of mean log2 (Cy5/Cy3) ratio against
distance along each individual chromosome (Mb). Chromosome
copy number changes were scored as hemizygous loss if the log2
ratio was ranging from 20.2 to 20.7, and homozygous deletion if
.20.7, or genomic gain for log2 ratio of 0.2 to 0.5, and
amplification if .0.5. Copy number changes seen on the sex
chromosomes were excluded in the analysis.
Multiplex Genomic PCR
Multiplex PCR permitted a semi-quantitative assessment of
DNA amplification/loss. GAPDH gene was selected as an internal
control. We amplified CCND1 and the internal control simulta-
neously. For CCND1, a pair of primers (forward: 59-tgctgcgaagtg-
gaaaccat and reverse: 59-caacaagttgcagggaagtc) generated a PCR
product of 227 bp. For GAPDH, a pair of primers (forward: 59-
gcctcactccttttgcagac and reverse: 59-gatgaccttgcccacagcct) gener-
ated a PCR product of 157 bp. PCR reactions were performed in
a final volume of 20 ml containing 200 mM deoxynucleotide
triphosphates, 2.5 mM MgCl2, 50 ng DNA, 0.5 mM each
oligonucleotide and 0.5 U AmpliTaq GOLD (Applied Biosystems,
Foster City, CA). Reaction conditions were as follows: an initial
denature at 95uC for 10 min followed by 30 cycles of 95uC for
30 s, 60uC for 30 s, 72uC for 30 s and a final extension at 72uC for
10 min. PCR products were separated on 2% agarose gels and
visualized. All reactions were carried out at least twice in
independent experiments.
Semi-quantitative Reverse Transcription PCR
Total RNA were extracted from cell pellets using TRI Reagent
(Molecular Research Centre, Cincinnati, OH). Reverse transcrip-
tion PCR (RT-PCR) was performed as described [43], using
GAPDH as a control. The primers for all genes will be provided
upon request. The PCR program utilized an initial denaturation at
95uC for 10 min, followed by 30 cycles of reaction (94uC for 30 s,
55uC for 30 s and 72uC for 30 s) (or 23, 25 cycles for CCND1),
with a final extension at 72uC for 10 min.
ESCC Tissue Microarray (TMA)
For each case, both tumor and normal tissues were duplicated
with a diameter of 1 mm on a glass slide. Before sample
acquisition, HE-stained FFPE slide of each case was observed
under a microscope and the locations of typically characteristic
morphology of ESCC and surrounding normal tissues were
circled. Samples were taken from the circled locations in the
paraffin block using the Beecher Instruments Tissue Arrayer
(Silver Springs, MD). For each block, two 1 mm cores were
punched from the circled regions in the donor block and arrayed
on the recipient block to ensure the representation of the samples,
and avoid missing information due to a loss of tissue cores. A total
of 171 ESCC specimens, 54 specimens of corresponding normal
mucosa were arrayed on two recipient blocks. Tissue microarray
sections (4 mm) were cut 24 h before immunohistochemistry.
Automated Immunohistochemistry
Immunohistochemistry was performed with a Ventana Bench-
mark XT autostainer (Ventana, Tuscon, USA), using monoclonal
rabbit anti-human CCND1/cyclin D1 (clone SP4) and mono-
clonal mouse anti-human b-catenin (Clone b-Catenin-1) from
DAKO (Glostrup, Denmark) with Ventana Ultraview kits
(Ventana, Tucson, USA). Slides were incubated for 24 min at
37uC with primary antibodies. Diaminobenzidine or 3-amino-9-
ethylcarbazole was used as chromogens and slides were counter-
stained with haematoxylin before mounting. Both chromogens
used on regular full sections before TMA testing gave concordant
results in terms of both surfaces and intensities of immunostaining.
Negative controls were created by omission of primary antibody
and replacement with phosphate buffered saline (PBS).
The CCND1 and b-catenin expression levels were determined
semi-quantitatively using a four-tiered scoring system, based on
the positive nuclear staining fraction of tumor cells (grade 0=0–
10%; grade 1+=11–25%; grade 2+=26–50%; grade 3+=51–
100%). A score of 0 was considered negative while a score of 1+,
2+ or 3+ was considered positive. For b-catenin, staining in
cytoplasm may have been present but was not included in the
determination of positivity.
Fluorescence in Situ Hybridization (FISH)
For FISH analysis of CCND1 gene amplification, two direct-
labeled probes were used, Vysis CCND1/CEP11 FISH Probe Kit
including LSI CCND1 (11q13) SpectrumOrange against CCND1
(11q13) and CEP11 SpectrumGreen (Vysis/Abbott, IL, USA)
against the centromere of chromosome 11. FISH analysis was
done according to ‘‘LSI Locus Specific Identifier DNA probes’’
from Vysis. The CCND1 gene to chromosome 11 centromere ratio
was measured in at least 60 nuclei from tumor cells and an average
score was taken. Observing more than two copies of CCND1 for
each chromosome 11 was considered to be a positive sign for
CCND1 gene amplification.
CCND1 Amplification in Esophageal Cancer
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Statistical analysis was performed using SPSS version 12.0. The
association between FISH and IHC results and the clinico-
pathological variables are performed using the x
2 -test. For all
tests, a p-value of ,0.05 was considered to be statistically
significant.
Supporting Information
Figure S1 Whole genome profiles of 10 ESCC cell lines
by 1-Mb aCGH. Normalized log2 signal intensity ratios were
plotted using SeeGH software. A log2 signal ratio of 0 represents
equivalent copy number between the sample and the reference
DNA (details in Materials and Methods). Cytoband pattern for
each chromosome is to the left for each plot. Vertical lines denote
log2 signal ratios from 22t o+2 with copy number increases to the
right and decreases to the left. Each black dot represents a single
BAC clone.
(TIF)
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